Recently, the EMPA-REG OUTCOME study and CANVAS program have shown that the selective SGLT2 inhibitors, empagliflozin and canagliflozin, significantly decrease the risk of cardiovascular death or hospitalized heart failure in type 2 diabetic patients who suffer a high risk of cardiovascular diseases [14,15]. Here, SLC5A2 is linked to heart failure.